<DOC>
	<DOCNO>NCT00093379</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine oxaliplatin , work different way stop tumor cell divide stop grow die . Capecitabine may stop growth tumor cell stop blood flow tumor . Radiation therapy use high-energy x-rays damage tumor cell . Capecitabine oxaliplatin may make tumor cell sensitive radiation therapy . Combining capecitabine oxaliplatin radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give capecitabine oxaliplatin together radiation therapy work treat patient stage II stage III anal cancer .</brief_summary>
	<brief_title>Capecitabine , Oxaliplatin , Radiation Therapy Treating Patients With Stage II Stage III Anal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine time treatment failure patient stage II-IIIB squamous cell carcinoma anal canal treat capecitabine , oxaliplatin , radiotherapy ( i.e . Capecitabine ( Xeloda ) /Oxaliplatin ( Eloxatin ) With Concomitant Radiotherapy ( XRT ) shorten XELOX/XRT ) . - Determine toxic effect regimen patient . Secondary - Determine complete response rate patient treat regimen . - Determine 2-year local regional control patient treat regimen . - Determine 2-year colostomy-free survival patient treat regimen . - Determine 2-year median overall survival patient treat regimen . - Determine 2-year progression-free survival patient treat regimen . OUTLINE : Patients receive oral capecitabine* twice daily day 1-2 , 6-10 , 20-24 , 27-31 , 41-42 , undergo radiotherapy* daily day 1-3 , 6-10 , 13-17 , 20-24 , 27-31 , 34-38 , 41-42 . Patients also receive oxaliplatin intravenous ( IV ) 2 hour day 1 , 8 , 22 , 29 . Treatment continue absence disease progression unacceptable toxicity . NOTE : *Patients T3-4 lesion also receive oral capecitabine twice daily undergo radiotherapy daily day 43 44 . Patients follow 4-6 12 week periodically thereafter . PROJECTED ACCRUAL : A total 71 patient accrue study .</detailed_description>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Previously untreated patient histologically proven squamous cell carcinoma anal canal . 2 . American Joint Committee Cancer ( AJCC ) stage IIIIIB ( TX 14 , NX , MO ) . 3 . Age &gt; /= 16 yr old . 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Scale ( PS ) 01 . 5 . Adequate organ function include : Absolute neutrophil Count ( ANC ) &gt; /= 1,500/uL , Platelets &gt; /= 100,000/uL , Total bilirubin &lt; /= 1.5 * upper limit normal ( ULN ) , aspartate aminotransferase ( AST SGOT ) /alanine aminotransferase ( ALT SGPT ) &lt; /= 3 * ULN , Creatinine &lt; /= 1.5mg/dL Creatinine Clearance ( CrCL ) &gt; /= 50 cc/min . 6 . Patients may measurable nonmeasurable disease . Patients measurable disease , define modify Response Evaluation Criteria Solid Tumors ( RECIST ) criterion , least one lesion accurately measure least one dimension long diameter record &gt; /= 20 mm use conventional technique &gt; /= 10 mm spiral CT scan ( minimum lesion size less double slice thickness ) . Lesions see colonoscopy barium study consider measurable lesion . 7 . A negative pregnancy test woman childbearing potential , within two week initiate treatment . 8 . The effect oxaliplatin capecitabine develop human fetus recommend therapeutic dose unknown . For reason cytotoxic agent know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 9 . Ability understand willingness sign write informed consent/authorization document . 1 . Prior chemotherapy oxaliplatin , capecitabine , 5fluorouracil . 2 . Prior radiation pelvis . 3 . Prior surgery anal cancer exclude prior biopsy . 4 . Known history dihydropyrimidine ( DPD ) deficiency . 5 . Known history hypersensitivity platinumcontaining compound . 6 . Peripheral neuropathy &gt; /= grade 2 Common Terminology Criteria Adverse Events ( CTCAE ) 3.0 . 7 . Calculated creatinine clearance ( CrCl ) &lt; 50 cc/min . 8 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit adherence study requirement . 9 . Gastrointestinal tract disease result inability take oral medication requirement intravenous ( IV ) alimentation . 10 . Because unknown potential risk adverse event nurse infant secondary treatment mother oxaliplatin capecitabine , breast feeding discontinue . 11 . Because know interaction capecitabine coumadin , patient take coumadin ineligible . Patients request discontinue coumadin utilize Lovenox agreeable . Patients must discontinue coumadin 7 day initiate therapy . 12 . No prior malignancy ( exclude nonmelanomatous skin neoplasm ) past 5 year . 13 . HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction capecitabine oxaliplatin . This exclusion patient safety since patient immune deficiency increase risk lethal infection treat marrowsuppressive therapy , HIVpositive anal canal cancer patient see institution . This hinder u accrue enough patient adequately test safety regimen population . 14 . Patients symptomatic pulmonary fibrosis .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>stage II anal cancer</keyword>
	<keyword>stage IIIA anal cancer</keyword>
	<keyword>stage IIIB anal cancer</keyword>
	<keyword>squamous cell carcinoma anus</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Eloxatin</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>XRT</keyword>
</DOC>